Extension Study Of Tanezumab In Osteoarthritis
NCT00809783 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2147
Last updated 2021-05-10
Summary
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
Conditions
Interventions
- BIOLOGICAL
-
tanezumab
Tanezumab 10 mg
- BIOLOGICAL
-
tanezumab
Tanezumab 5 mg
- BIOLOGICAL
-
tanezumab
Tanezumab 2.5 mg
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-06
- Primary Completion
- 2010-11-02
- Completion
- 2011-06-23
Countries
- United States
Study Locations
More Related Trials
-
Tanezumab and Nerve Function In Arthritis Patients
NCT00863772 ·Status: TERMINATED ·Phase: PHASE3
-
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01347983 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
NCT02709486 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
NCT00883753 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02353780 ·Status: TERMINATED ·Phase: PHASE4
-
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
NCT00805467 ·Status: TERMINATED ·Phase: PHASE2
-
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524 ·Status: COMPLETED ·Phase: PHASE1
-
Long Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00924664 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
NCT01187563 ·Status: COMPLETED
-
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
NCT01063803 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
NCT02093026 ·Status: COMPLETED ·Phase: PHASE2
-
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
NCT01643928 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
NCT00443651 ·Status: COMPLETED ·Phase: PHASE3
-
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis
NCT01952509 ·Status: COMPLETED
-
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis
NCT02721004 ·Status: COMPLETED
-
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
NCT01665430 ·Status: TERMINATED ·Phase: PHASE3
-
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
NCT01649804 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01089023 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
NCT02480153 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NCT00720798 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
NCT01730456 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
NCT03605251 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
NCT02097745 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
NCT05849727 ·Status: TERMINATED ·Phase: PHASE2
-
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
NCT00995449 ·Status: TERMINATED ·Phase: PHASE2